Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03755518
Title An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Celgene
Indications

myelofibrosis

Therapies

Fedratinib

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.